CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This activity is intended for medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of biliary tract cancers.
  
  LEARNING OBJECTIVES

  • Discuss the biological justification for the evaluation of immune checkpoint inhibitors for advanced biliary tract cancers (BTCs) and develop strategies to optimally incorporate anti-PD-1/PD-L1 antibody-based approaches into the care of patients with these diseases.
  • Recognize the molecular heterogeneity of cholangiocarcinomas and other biliary tract cancers, and appreciate the biological rationale for efforts to exploit documented abnormalities in patients with these diseases.
  • Assess key datasets supporting the recent FDA approvals of fibroblast growth factor receptor (FGFR) inhibitors for previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or other rearrangement to optimally select and sequence these agents.
  • Develop an understanding of available clinical trial findings supporting the use of IDH inhibitors for patients with advanced cholangiocarcinoma and an IDH1 mutation in order to determine the applicability of this therapeutic strategy to current clinical practice.
  • Evaluate available and emerging clinical trial findings with HER2-directed therapies in patients with HER2-positive biliary tract cancers, and contemplate the current and potential future utility of these agents for appropriately selected individuals.
  • Assess the scientific rationale for targeting the MDM2-p53 pathway for patients with advanced biliary tract cancers and understand the mechanisms of action, available data and ongoing studies with novel MDM2-p53 antagonists.
  • Recall available and emerging data with investigational agents and strategies currently in clinical testing for biliary tract cancers, and refer eligible patients for trial participation.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  Audio Program: Research To Practice designates this enduring material for a maximum of 3 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  
  Video Program: Research To Practice designates this enduring material for a maximum of 2.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  Successful completion of these CME activities, which includes participation in the evaluation components and short post-tests, enables the participant to earn up to 3 (audio) and 2.5 (video) Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  
  Please note, these programs have been specifically designed for the following ABIM specialty: medical oncology.
  
  AMERICAN BOARD OF SURGERY (ABS) — CONTINOUS CERTIFICATION (CC)
  Successful completion of these CME activities, which includes participation in the evaluation component, enables the learner to earn credit toward the CME and Self-Assessment requirement(s) of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABS credit.
  
  Please note, these programs have been specifically designed for the following ABS practice area: complex general surgical oncology.
  
  PRIVACY POLICY
  Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
  
  HOW TO USE THIS CME ACTIVITY
  To receive credit for an activity in this series, the participant should review the CME information, listen to or view the MP3s, review the downloadable slide set, complete the post-test with a score of 80% or better and fill out the evaluation. Program location URLs are noted below:
  
  Audio Program: ResearchToPractice.com/BTCThinkTank2024 and evaluation ResearchToPractice.com/BTCThinkTank2024/CME.
  
  Video Program: ResearchToPractice.com/BTCThinkTank2024/Video and evaluation ResearchToPractice.com/BTCThinkTank2024/Video/CME.
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
  
  Lipika Goyal, MD, MPhil
  Director of Gastrointestinal Oncology
  Stanford Cancer Center
  Associate Professor
  Stanford University School of Medicine
  Palo Alto, California
  
  Consulting Agreements: AbbVie Inc, Agenus Inc, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Compass Therapeutics, Exelixis Inc, Kinnate Biopharma, Merck, Relay Therapeutics, Servier Pharmaceuticals LLC, Surface Oncology, Taiho Oncology Inc, TransThera Biosciences, Tyra Biosciences, Inc; Contracted Research: Alyssum Therapeutics, Boehringer Ingelheim Pharmaceuticals Inc, Genentech, a member of the Roche Group; Data and Safety Monitoring Board/Committee: AstraZeneca Pharmaceuticals LP.
  
  James J Harding, MD
  Assistant Attending
  Memorial Sloan Kettering Cancer Center
  Assistant Professor of Medicine
  Weill Cornell Medical College
  New York, New York
  
  Advisory Committees: Amgen Inc, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Jazz Pharmaceuticals Inc, Merck, RayzeBio, Servier Pharmaceuticals LLC, Zymeworks Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Codiak BioSciences, Jazz Pharmaceuticals Inc, Kinnate Biopharma, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Zymeworks Inc; Data and Safety Monitoring Board/Committee: Merck.
  
  Milind Javle, MD
  Professor
  Department of Gastrointestinal Medical Oncology
  Division of Cancer Medicine
  The University of Texas MD Anderson Cancer Center
  Houston, Texas
  
  Advisory Committees: AbbVie Inc, Agios Pharmaceuticals Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Biocartis, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Daiichi Sankyo Inc, EMD Serono Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, Lilly, Meclon Pharmaceuticals, MSD, Novartis, OncoSil Medical Ltd, QED Therapeutics, Servier Pharmaceuticals LLC, Taiho Oncology Inc, TransThera Sciences; Contracted Research: Agios Pharmaceuticals Inc, Bristol Myers Squibb, Boehringer Ingelheim Pharmaceuticals Inc, Celgene Corporation, Daiichi Sankyo Inc, EMD Serono Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, Lilly, Meclon Pharmaceuticals, MSD, Novartis, OncoSil Medical Ltd, QED Therapeutics, Servier Pharmaceuticals LLC, Taiho Oncology Inc, TransThera Sciences.
  
  Robin K (Katie) Kelley, MD
  Professor of Clinical Medicine, Division of Hematology/Oncology
  Helen Diller Family Comprehensive Cancer Center
  University of California, San Francisco (UCSF)
  San Francisco, California
  
  Advisory Committees (Payments to Institution): Agios Pharmaceuticals Inc, AstraZeneca Pharmaceuticals LP, Exelixis Inc, Ipsen Biopharmaceuticals Inc, Merck; Consulting Agreements (Payments to Self): Compass Therapeutics, Exact Sciences Corporation, GSK, J-Pharma Co Ltd, Kinnate Biopharma, Moderna, Regeneron Pharmaceuticals Inc, Tyra Biosciences; Contracted Research (Payment to Institution for Trial Conduct): Agios Pharmaceuticals Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, Compass Therapeutics, EMD Serono Inc, Exelixis Inc, Genentech, a member of the Roche Group, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Partner Therapeutics, QED Therapeutics, Servier Pharmaceuticals LLC, Surface Oncology, Taiho Oncology Inc, Tyra Biosciences; Independent Data Monitoring Committees (Unpaid Service): Genentech, a member of the Roche Group, Merck.
  
  EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, Hologic Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Legend Biotech, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSeraTherapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  These activities are supported by educational grants from Boehringer Ingelheim Pharmaceuticals Inc, Daiichi Sankyo Inc, and Taiho Oncology Inc.
  
  Release date: September 2024
  Expiration date: September 2025
  
  After completing the post-test, learners may download and review the answers here in order to identify further areas of study.